Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID Clear all
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

NCT05736861
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

NCT04762680
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
3,159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

TD-0903 for ALI Associated With COVID-19

NCT04402866
View directory record Official record
Conditions
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
Interventions
TD-0903, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Duarte, California • Denver, Colorado • Sebring, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

NCT07861542
View directory record Official record
Conditions
COVID-19
Interventions
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M
Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
20
States / cities
Fair Oaks, California • Doral, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 Treatment in Severe COVID-19 Patients

NCT04483973
View directory record Official record
Conditions
Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

NCT05050682
View directory record Official record
Conditions
Healthy
Interventions
PF-07304814
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 28, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT04910269
View directory record Official record
Conditions
COVID, SARS-CoV2 Infection, Covid19
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
Biological · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Mather, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational

Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

NCT04854980
View directory record Official record
Conditions
Covid19, Cancer
Interventions
Blood Sample
Other
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)

NCT07770022
View directory record Official record
Conditions
Long Covid
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

Water-based Activity to Enhance Recovery in Long COVID-19

NCT06142253
View directory record Official record
Conditions
Long COVID
Interventions
WATER+CT, Usual Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Not listed No phase listed Observational

Cardiovascular Manifestations of COVID-19

NCT04335630
View directory record Official record
Conditions
Cardiovascular Diseases, COVID
Interventions
Electrocardiogram, telemetry, echocardiogram, laboratory values
Diagnostic Test
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia

NCT05566379
View directory record Official record
Conditions
Long COVID, Dysautonomia
Interventions
Mindfulness - Mindful Awareness Practices ( MAPs)
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Randomized Open Investigation Determining Steroid Dose

NCT04834375
View directory record Official record
Conditions
Covid19
Interventions
Weight-based dexamethasone dose
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )

NCT05281692
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Enhanced Preservation Media (EPM-IX)
Diagnostic Test
Lead sponsor
Convergent Genomics, Inc.
Network
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Apilimod Dimesylate Capsule, Placebo
Drug · Other
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780281
View directory record Official record
Conditions
COVID-19
Interventions
VIR-7831, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Vitamin D Testing and Treatment for COVID 19

NCT04407286
View directory record Official record
Conditions
Covid 19, Vitamin D Deficiency
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Response in Treated MS Patients

NCT05060354
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
Blood draw
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 28, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Tofacitinib for Treatment of Moderate COVID-19

NCT04415151
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Tofacitinib 10 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Withdrawn Phase 2 Interventional

Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

NCT04363866
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 28, 2026, 9:30 PM EDT
Withdrawn Phase 2 Interventional

Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04784754
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 28, 2026, 9:30 PM EDT